Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05676450 · ClinicalTrials.gov registry record · NA
Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas
A NA study of Lymphoma, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 517
- Enrollment target
- 2
- Study locations
NCT05676450 is a NA study of Lymphoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 517 participants, roughly in line with the 482-participant average among 299 other Lymphoma trials with a reported enrollment target. The trial reports 2 study locations across 1 state.
The verdict
NCT05676450, a NA study of Lymphoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 517 participants
- Enrollment target
- 2
- Study locations
Study Summary
To test the feasibility of collecting cell-free DNA (cfDNA) samples from DLBCL patients before and after treatment. cfDNA is DNA traveling in your blood outside of a cell and is easily collected from blood samples drawn using the vein puncture method.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST cell-free DNA
Study Locations (2)
Texas
- MD Anderson Cancer Center - Houston
- Cancer Therapy and Research Center at The UT Health Science Center at San Antonio - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 517 participants |
| Start Date | 2023-02-23 |
| Est. Completion | 2026-08-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05676450
The ClinicalTrials.gov registry entry for NCT05676450 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 517 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 482-participant average among 299 other Lymphoma trials with a reported enrollment target. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which cell-free DNA is the first listed.
NCT05676450 reports 2 study locations spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05676450 about?
NCT05676450 is a clinical study titled "Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas". To test the feasibility of collecting cell-free DNA (cfDNA) samples from DLBCL patients before and after treatment. cfDNA is DNA traveling in your blood outside of a cell and is easily collected from blood samples drawn using the vein puncture method.
What is the current status of trial NCT05676450?
This trial is currently recruiting. It is a NA study. The enrollment target is 517 participants. The study started on 2023-02-23. Estimated completion is 2026-08-31.
What conditions does trial NCT05676450 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT05676450?
The interventions under investigation include: cell-free DNA (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05676450?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05676450 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
RECRUITING · NA
-
WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)
RECRUITING · NA
-
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
RECRUITING · NA
-
An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers
RECRUITING · NA
-
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
RECRUITING · NA
-
Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Stem Cell Transplantation
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.